Who is sponsoring NCT03739970?

NCT03739970 is sponsored by Yonsei University.

What drugs are being tested in NCT03739970?

Interventions in NCT03739970: Investigational Product (Silk Peptide), Control Group - Placebo Product.

What condition does NCT03739970 study?

NCT03739970 studies Normal Healthy Subjects.

Is NCT03739970 still recruiting?

NCT03739970 is currently status unknown. Last updated 14 November 2018.

Last reviewed 2018-11-14 · How we verify

NCT03739970

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Trial of Silk Peptide for the Evaluation of Efficacy on Immune Function

Status unknown NA Last updated 14 November 2018

What this trial tests

NA trial testing Investigational Product (Silk Peptide) in Normal Healthy Subjects in 110 participants. Status unknown.

Timeline

15 November 2018

Primary endpoint
29 January 2019

28 February 2019

Quick facts

Lead sponsor	Yonsei University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	110
Start date	15 November 2018
Primary completion	29 January 2019
Estimated completion	28 February 2019
Sites	1 location across South Korea

Drugs / interventions tested

Investigational Product (Silk Peptide)
Control Group - Placebo Product

Conditions studied

Normal Healthy Subjects — all drugs for Normal Healthy Subjects →

Sponsor

Yonsei University

Who can join

50 and older, any sex, with Normal Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a 8-week, randomized, double-blind, placebo-controlled clinical trial of Silk Peptide for the evaluation of efficacy on immune function enhancement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03739970 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 14 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03739970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing